Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTAGORAS: Protamine application in patients undergoing transfemoral TAVR
2024-512024-10-01Phase 3Authorised
- Sponsor
- LMU Klinikum
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3 trial of protamine in aortic stenosis (AS), sponsored by LMU Klinikum. Primary endpoint: Primary: Bleeding grade ≥ type 2 (VARC) until 60 hours post TAVR procedure. Planned start Mar 2025; status: authorised.
02
Drugs
protamine
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on 2024-512024-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512024-10-01.